FDA Warns Bentley Laboratories Over CGMP, Testing, and Validation Failures

by

FDA issued a warning letter to Bentley Laboratories following a March 2026 inspection, citing significant CGMP violations for finished pharmaceuticals. FDA found inadequate investigations of out-of-specification stability and cleaning results, deficient root-cause analysis and CAPA, unjustified specification changes, and insufficient quality-unit oversight. The agency also cited inadequate incoming-component identity and impurity testing, reliance on supplier certificates of analysis without establishing reliability, and weaknesses in supplier qualification. Manufacturing and cleaning processes were not adequately validated or revalidated after changes, and validation protocols were not fully executed. FDA also determined that two acne products were unapproved new drugs and misbranded, and acknowledged the firm’s commitment to suspend certain OTC drug production.

FDA Warns Kellin Chemicals Over Refused API Facility Inspection

by

FDA issued a warning letter to Kellin Chemicals (Zhangjiagang) Co., Ltd., an establishment registered as an active pharmaceutical ingredient supplier to finished-drug manufacturers serving the U.S. market. The firm’s U.S. agent told FDA that the company refused a preannounced inspection planned for July 7–11, 2025. FDA states that drugs made, processed, packed, or held there are adulterated under section 501(j) because inspection was refused. FDA may withhold application or supplement approvals listing the facility and may detain or refuse relevant U.S. shipments. The company was asked to respond within 15 working days and could request an inspection.

FDA Cites Curia New York for API Data Integrity and Computerized System Failures

by

FDA issued a warning letter to Curia New York, Inc. after its January 28–February 5, 2026 inspection of the Rensselaer API manufacturing facility. It states the firm’s APIs are adulterated because manufacturing methods, facilities, or controls did not conform to CGMP. FDA cited incomplete laboratory records and thousands of unexplained HPLC/UPLC injections, including use of the Empower “Developer” role; discarded original records and review of photocopies; and shared computerized-system credentials. FDA found the firm’s responses inadequate in scope or supporting evidence. It requested independent investigations, retrospective data-integrity and computerized-system assessments, product-impact and risk evaluations, laboratory remediation, and a global CAPA plan.

FDA Cites Sterile Injectable CGMP Violations at Fresenius Kabi Facility

by

FDA issued a warning letter to Fresenius Kabi AG after a January 27 to February 18, 2026 inspection identified significant CGMP violations at its Melrose Park sterile injectable facility. FDA cited inadequate investigations of endotoxin and bioburden signals, media fill failures, complaints, and biological particulate contamination; deficient aseptic process simulations and cleanroom practices; and inadequate visual inspection, facility, and equipment controls. The letter states that investigations overrelied on passing finished-product tests and lacked supported root causes, broad scope, and CAPA effectiveness checks. It also describes recalls of three famotidine injection batches and, following FDA discussions, six batches of other injectable products. FDA requested independent assessments, retrospective reviews, remediation plans, and a response within 15 business days.

PIC/S Revises GMP Guide Annex 19 on Reference and Retention Samples

by

PIC/S revised its GMP Guide for Medicinal Products to version PE 009-18, incorporating the revised Annex 19 on reference and retention samples. The revision primarily concerns Section 9, addressing samples for parallel imported, parallel distributed, and parallel traded products. A note specifying that Section 9 applies only where these activities are covered by local legislation has been retained. The PIC/S Committee adopted the revision by written procedure on 22 September 2026. PE 009-18 enters into force on 24 September 2026, coinciding with the revised EU Annex 19. Non-EEA PIC/S Participating Authorities and Applicants have been invited to transpose Annex 19 into their GMP Guides.

EMA Announces First Bilateral Meeting with APIC

by

EMA announced its first bilateral meeting with the Active Pharmaceutical Ingredients Committee (APIC), organised within EMA’s annual bilateral meetings with industry stakeholder organisations. The meeting is scheduled for 2 September 2026 from 15:30 to 17:30 CEST at EMA in Amsterdam, the Netherlands. Its stated purpose is to exchange views and promote dialogue on topics of common interest. Participation is by invitation only. The page lists an agenda, first published on 31 July 2026 and updated on 23 September 2026, and a highlights report, reference EMA/199326/2026, first published on 23 September 2026.

FDA Warning Letter: Aseptic Processing and Media-Fill Deficiencies at Empower Pharmacy

by

FDA states that its November 3-14, 2025, inspection found Empower Pharmacy’s compounded semaglutide and tirzepatide products did not meet section 503A conditions, making the ineligible products subject to CGMP. Investigators observed that sterile products were prepared under insanitary conditions. Smoke studies did not adequately demonstrate unidirectional airflow under dynamic conditions, and media fills were not conducted under the most challenging conditions. FDA also cited inadequate maintenance systems for equipment controlling aseptic conditions, deficient procedures to prevent microbiological contamination and validate aseptic and sterilization processes, inadequate environmental monitoring, insufficient production and process-control procedures, and failure of the quality control unit to ensure CGMP compliance and product specifications. In reviewing corrective actions, FDA said a revised smoke study remained unfinalized. It also identified unexplained vial-count discrepancies, missing or unclear media-fill records, undefined “N/A” entries, and transcription of original results onto a revised form without a clear audit trail, authorization, or justification.

FDA Warning Letter: KDC/ONE Chatsworth cited for testing, OOS investigation, and storage deficiencies

by

FDA inspected KDC/ONE Chatsworth’s drug manufacturing facility from March 31 to April 3, 2026, and cited significant CGMP violations involving OTC finished pharmaceuticals. The agency states that the firm lacked scientifically sound finished-product specifications and did not perform specified contaminant testing at release or during stability studies, despite known degradation and reaction pathways and notification of contamination linked to products recalled in Canada. FDA said the firm did not determine whether recalled batches reached the United States, assess U.S. consumer risk, identify other potentially affected batches, or demonstrate that its proposed third-party laboratory was qualified. FDA also observed inadequate investigations of viscosity OOS stability results, including insufficient root-cause determination, CAPA, specification justification, and risk assessment for distributed products. In addition, FDA found inadequate warehouse temperature monitoring and procedures, including storage above labeled conditions and internal limits. FDA considered the firm’s responses inadequate and stated that the quality unit was not able to fully exercise its authority and responsibilities.

Par Health Recalls Two Dexmedetomidine Injection Lots for Particulate Matter

by

Par Health announced a voluntary nationwide recall to the hospital level of two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 400 mcg/100 mL, after particulate matter was identified as cellulose or stopper material. The affected lots are 87558, expiring February 2027, and 88802, expiring April 2027. They were distributed to wholesalers between May 13 and June 29, 2025. Wholesalers and hospital pharmacies were instructed to stop use and distribution and return existing inventory. The announcement states that particulate administration could cause life-threatening vascular consequences. No related adverse events had been reported.

Otsuka ICU Medical Recalls Sodium Chloride Injection Lot for Potential Potassium Chloride Mix-Up

by

Otsuka ICU Medical LLC announced a voluntary nationwide user-level recall of one lot of 0.9% Sodium Chloride Injection, USP, 100 mL, after a customer complaint identified a potential product mix-up. Sodium chloride overwraps from lot 1042188, NDC 0990-7984-23, may contain 10-mEq Potassium Chloride Injection bags from lot 1035181. The affected lot was manufactured on November 13, 2025, distributed in the United States from December 30, 2025, through June 22, 2026, and expires October 31, 2027. The company reported no related adverse events to date. Customers and distributors were instructed to inspect inventory, quarantine and discontinue use, and return affected product.